Categories
Lung Cancer

Kathy Griffin announces lung cancer battle on Twitter, says she’s a recovering addict in ‘Nightline’ interview [Video]

Kathy Griffin has weathered her fair share of controversy. The comedian has claimed she’d been banned from various shows over her decadeslong career.

But she says nothing could compare to the fallout she experienced from her 2017 photoshoot in which she held a mask that appeared to be bloodied with then President Donald Trump’s likeness. By June 2020, she was in the throes of a painkiller addiction and even attempted suicide. Yet, she’s still here.

“Whether I like it or not, I think I’m a resilient survivor,” she told ABC News’ Juju Chang in an exclusive interview last week.

Watch Kathy Griffin’s full interview on “Nightline” on Monday, Aug. 2, on ABC

Griffin says her life became consumed by the consequences of the Trump photoshoot. After her career of self-described “in-your-face” comedy, the world apparently deemed that this image had gone too far.

Amid the fallout, Griffin said that she …

Watch/Read More
Categories
Lung Cancer

Oncotarget | Effects of Metformin and Rapamycin in Pancreatic Cancer [Video]

Oncotarget published this trending research paper on May 26, 2020, entitled, "An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma" by researchers from the Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD; Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ; Molecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai City, China; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.Abstract:Purpose: Metformin combined with the mTOR inhibitor rapamycin showed potential synergistic anti-tumor activity in preclinical studies in pancreatic ductal adenocarcinoma (PDA). This phase 1b study (NCT02048384) was conducted to evaluate the feasibility and activity of metformin +/– rapamycin in the maintenance setting for unselected patients with metastatic PDA (mPDA) treated with chemotherapy.Materials and Methods: Eligible patients with stable or responding mPDA after ≥ 6 months on chemotherapy were randomized 1:1 to metformin alone (Arm A) or with rapamycin (Arm B), stratified by prior treatment with FOLFIRINOX. Fluorodeoxyglucose (FDG) PET scans and peripheral blood mononuclear cells were obtained for exploratory analyses.Results: 22 subjects (11 per arm) received treatment per protocol. Median PFS/OS were 3.5 and 13.2 months respectively, with 2 year OS rate of 37%; there were no differences between arms. No responses were observed by RECIST; however, decreases in FDG avidity and/or CA19-9 were observed in several long-term survivors. Treatment related adverse events of Grade ≥ 3 occurred in 0% vs 27% of patients in Arm A vs B and were asymptomatic hematologic or electrolyte abnormalities that were not clinically significant. Improved survival was associated with low baseline neutrophil: lymphocyte ratio, baseline lack of assessable disease by PET, and greater expansion of dendritic cells following treatment.Conclusions: Metformin +/– rapamycin maintenance for mPDA was well-tolerated and several patients achieved stable disease associated with exceptionally long survival. Further prospective studies are needed to clarify the role of these agents in the maintenance setting and to enhance patient selection for such approaches.Press release - https://www.oncotarget.com/news/pr/an-exploratory-study-of-metformin-and-rapamycin-as-maintenance-therapy/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27586DOI - https://doi.org/10.18632/oncotarget.27586Full text - https://www.oncotarget.com/article/27586/text/Correspondence to - Dung T. Le - dle@jhmi.edu Keywords - pancreatic cancer, mTOR inhibition, maintenance therapy, metformin, rapamycinAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia ContactMEDIA@IMPACTJOURNALS.COM18009220957

Categories
Lung Cancer

Live Study With Me For Finals | Pomodoro 50/10 | Quiet Study Session [Video]

✨⏰📚⬇️ CLICK BELOW FOR SCHEDULE ⬇️📚⏰✨ ✨ Live Study With Me Pomodoro✨ Seven Hours | 50/10✨ Hudson River Views in Manhattan✨ Current subscriber count → 2,010Hi friends :)Study with me as I work towards finals, while completing a PhD in Musicology at All Hallows College, DCU (Ireland). I'm currently living in Manhattan, NY and I always, ALWAYS work better when studying with other pals and peeps, so thank you for studying with me today. 🟢 Today's study with me is four sessions long.🟢 We start at 9:00am and we finish at 2:00pm.🟢 The timer/session is on the screen, and a bell will ring at the beginning and end of each session and break. 09.00 - 09.50 Session 109.50 - 10:00 Tea Break10.00 - 10.50 Session 210.50 - 11.00 Tea Break11.00 - 11.50 Session 311.50 - 12.00 Tea Break 12.00 - 12.50 Session 4 12.50 - 13.00 LUNCH, GREAT SUCCESS!I'm really enjoying the winter holiday vibes in Manhattan right now so I've got some candles lit, hot coffee at. hand and a crackling fire playlist on in the background.Let me know in the comments - what are you planning to study today? 🤓Hugs,Holly x_________________________________________________✨ FAQ ✨How old are you?I'm 29 and 13 months old.Where are you based?I'm Irish but have recently moved to MANHATTAN, BABY!!!!!What type of cancer are you getting treatment for?Stage IV oesophageal adenocarcinomaWhat drug are you on?An immunotherapy drug, called Nivolumab (Opdivo)What type of PhD research are you carrying out?Historical research into records of children's musical culture in IrelandWhich university are you studying at?All Hallows, College, Dublin City University____________________________✨ Say hi on Instagram :) or email @enquiries.hollyjane@gmail.com